11C]flumazenil ( DrugBank: Flumazenil )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03825601 (ClinicalTrials.gov)	February 1, 2019	21/1/2019	PET With [18F]Flumazenil as an Index of Neurodegeneration in MS	PET With [18F]Flumazenil as an Index of Neurodegeneration in MS: Sensitivity at an Early Disease Stage and Pathophysiological Meaning	Multiple Sclerosis;Relapsing-Remitting Multiple Sclerosis	Diagnostic Test: PET with [11C]Flumazenil	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Not yet recruiting	18 Years	55 Years	All	45	N/A	NULL
2	EUCTR2017-002636-16-NL (EUCTR)	09/10/2017	09/08/2017	Understanding problems with attention, memory and concentration in persons with multiple sclerosis	Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS	Multiple Sclerosis (MS). And specifically cognitive problems in MS.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [11C]flumazenil	VU University medical center Amsterdam	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Netherlands